Two Regulators Read the Same Cancer Trial. They Reached Opposite Conclusions.

AstraZeneca won European approval Thursday for a breast cancer drug the FDA rejected three weeks earlier — on the same trial data, for the same indication, in the same patients. The vote was six to three against. The divergence is not a close call dressed up as a split. It is a fundamental disagreement between two of the world's most consequential drug regulators about what kind of evidence a cancer drug needs to show before it can be sold.

The Committee for Medicinal Products for Human Use, the EMA's scientific advisory body, adopted a positive opinion for AstraZeneca's camizestrant on May 21, 2026. The drug, marketed as Etcamah, is indicated for adults with locally advanced or metastatic breast cancer harbouring an ESR1 mutation — a genetic alteration that develops in roughly 30 to 40 percent of patients treated with standard hormone therapy over approximately two years, and that renders those therapies less effective. Twenty-one days earlier, the FDA's Oncologic Drugs Advisory Committee voted six to three against recommending the same drug for the same patients.

The trial in question is SERENA-6, a Phase III study that broke with convention in a specific and consequential way. Rather than enrolling patients at initial diagnosis or at radiological progression, it used blood monitoring — circulating tumour DNA analysis — to identify patients whose cancers were developing ESR1 mutations while still appearing stable on scans. Those patients were then switched, blindly, from a standard aromatase inhibitor to camizestrant, a next-generation oral selective oestrogen receptor degrader, while continuing their CDK4/6 inhibitor. The theory: catch the resistance mechanism early, before the tumour visibly adapts. Intervene in the biology rather than the imaging.

The FDA's majority panellists were not persuaded that this constituted sufficient proof of clinical benefit. Their concern had two components, which are distinct even if AstraZeneca treated them as one. The first is the endpoint itself: PFS in this trial was measured from the point of the ctDNA-detected switch, not from randomisation at diagnosis. Critics of this design note that the comparator arm had no equivalent opportunity for a pre-progression therapeutic adjustment — patients there remained on a therapy that was, by definition, already losing efficacy. This creates an asymmetry the trial cannot fully resolve: the experimental arm gets an intervention the control arm does not, making the measured difference potentially attributable to the act of switching rather than to camizestrant's intrinsic superiority. The second concern is the maturity of overall survival data. At the time of analysis, the survival signal numerically favoured camizestrant, but the confidence interval crossed one — a hazard ratio of 0.87 with a 95 percent interval of 0.57 to 1.30 means a statistically meaningful survival benefit has not been established. In advanced breast cancer, where PFS surrogacy for OS is imperfect, the FDA has historically required either mature survival data or a compelling PFS signal with strong biological plausibility. SERENA-6's 56 percent PFS reduction is compelling numerically, but the trial design makes it difficult to interpret.

The EMA weighed these same concerns and reached a different conclusion. Its positive opinion rested heavily on a secondary endpoint — time to second progression, or PFS2 — which showed 25.7 months for the camizestrant arm versus 19.1 months for the comparator, a difference statistically significant at p equals 0.00373. PFS2 is not confounded by the switch design in the same way, because it measures the interval from second progression to second progression, capturing what happened after the initial therapeutic分歧 regardless of when the initial switch occurred. The EMA gave this endpoint substantial weight. The FDA panel did not find it sufficient to overcome their concerns about the primary.

What makes this split unusual is not that regulators disagree — they always have — but that the FDA had previously signalled enthusiasm for this programme. The agency granted Breakthrough Therapy Designation in May 2025 and accepted the New Drug Application in July 2025, both before the ODAC vote. The pipeline from BTD to rejection at advisory committee is uncommon. It suggests either that the internal FDA review identified concerns that were not apparent at the BTD stage, or that the advisory committee process surfaced problems that pre-decided reviewers had not fully considered. AstraZeneca has not withdrawn its US application. The FDA is not bound by ODAC recommendations, though it follows them in the vast majority of cases. Whether this is one of the exceptions — and what path, if any, might lead to a narrower US approval — is unresolved.

The stakes extend beyond this single drug. Camizestrant is a test case for the broader question of whether ctDNA-guided trial designs can serve as the evidentiary basis for oncology drug approvals. Liquid biopsy monitoring is increasingly embedded in academic and commercial cancer care, and several drug developers are designing trials that use molecular progression signals rather than radiographic ones as triggers for therapeutic switches. If the FDA's position is that this approach generates signals but not proof, the implications for that entire development strategy are significant. If the EMA's position — that ctDNA monitoring can constitute meaningful clinical evidence — becomes more widely adopted, European regulators may become a faster path to market for precision oncology drugs using these designs, creating a structural incentive for companies to pursue European approval first and use that as leverage in US regulatory conversations.

The patient population caught in the middle is not small. Approximately 200,000 patients globally begin first-line hormone therapy for HR-positive breast cancer each year. ESR1 mutations are a leading mechanism of treatment failure. For those patients, the difference between a drug that works and one that does not is measured in months without progression — not cure, not remission, but time before the cancer learns to resist. The EMA's approval means European oncologists can now prescribe Etcamah at their discretion. Whether health technology assessment bodies in individual European countries will reimburse it, and at what price, remains an open and consequential question.

Dr. Kevin Kalinsky, co-principal investigator of SERENA-6 and co-chair of the trial, called the ODAC outcome disappointing. His co-investigator, François-Clément Bidard of Institut Curie and Versailles University, did not publicly comment on the vote. Susan Galbraith, AstraZeneca's head of oncology research, framed the EMA opinion as validation of the trial's core concept. The FDA's public record frames the advisory committee's concerns in procedural language that amounts to the same thing: the data were not enough.

As Pink Sheet reported, the EU's endorsement of camizestrant signals confidence in a novel trial strategy the FDA was not prepared to validate. The EU and US regulatory systems have diverged before — the EMA approved alirocumab for cholesterol reduction over FDA objections in 2016; the FDA eventually followed — but those splits were about risk tolerance or political context, not about what constitutes the fundamental evidentiary standard for a novel trial design. The trial that generated those data is now the subject of genuine regulatory divergence. That is not a footnote. It is the story.